Targeting α5β1 integrin for imaging of tumor angiogenesis and antiangiogenic therapy (A10)

靶向 α5β1 整合素用于肿瘤血管生成成像和抗血管生成治疗 (A10)

• 批准号: 361989939
• 金额: --
• 依托单位: Institut für Allgemeine Pathologie und Pathologische Anatomie
• 依托单位国家: 德国
• 项目类别: Collaborative Research Centres
• 财政年份: 2017
• 资助国家: 德国
• 起止时间: 2016-12-31 至 2020-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/361989939?language=en
• 关键词: Targeting; integrin; imaging; tumor; angiogenesis

Although the transmembrane receptor αvβ3 integrin has been considered a specific cellular marker for angiogenic activity for decades, recent data suggest that the α5β1 integrin might be more suitable for this purpose. This project aims to exploit the potential of α5β1 integrin as a target for novel imaging probes and antiangiogenic radiotherapeutics, and to elucidate interplay and correlation of α5β1 integrin expression with that of other angiogenesis markers, such as αvβ3 integrin or the oncofetal slice variant of fibronectin, extradomain B.

虽然跨膜受体αvβ3整合素几十年来一直被认为是血管生成活性的特异性细胞标志物，但最近的研究表明，α5β1整合素可能更适合于这一目的。本项目旨在开发α5β1整合素作为新型成像探针和抗血管生成放射治疗靶点的潜力，并阐明α5β1整合素的表达与其他血管生成标记物的相互作用和相关性，如αvβ3整合素或纤维连接蛋白的癌胎儿切片变体B外域。